Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research
Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova Therapeutics (NASDAQ: ONTX) was reduced by Zacks Investment Research  from a “get” rating to a “hold” score in a research note released to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It concentrates on uncovering as well as establishing little molecule medication prospects to treat cancer cells. The Firm‘s items under different phases of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research experts additionally lately talked about the company. Noble Financial reissued a “get” rating and released a $11.00 cost objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and established a “purchase” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day relocating typical cost of $2.90 as well as a two-hundred day moving average rate of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) earnings per share for the quarter, covering experts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as an adverse internet margin of 8,294.27%. The firm had revenue of $0.06 million during the quarter, contrasted to the consensus price quote of $0.06 million. Throughout the very same quarter in the previous year, the firm uploaded ($ 0.45) EPS. En masse, research experts anticipate that Onconova Therapeutics will certainly publish -1.18 EPS for the existing year.

A variety of hedge funds have lately bought and sold shares of ONTX. GSA Funding Partners LLP bought a new placement in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Capital Management LP purchased a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a brand-new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC bought a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP bought a new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as other institutional financiers possess 13.36% of the business’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which takes part in the recognition and also advancement of oncology therapeutics. It concentrates on finding and developing tiny molecule drug prospects to treat cancer. The business was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Obtain a totally free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more information regarding research offerings from Zacks Investment Research, see Zacks.com.

This instantaneous news alert was generated by narrative science innovation and also monetary data from Market in order to offer readers with the fastest and also most precise coverage. This story was evaluated by Market’s editorial team prior to publication. 



Prior to you think about Onconova Therapeutics, you’ll intend to hear this.

Market keeps track of Wall Street’s premier and ideal performing research experts as well as the stocks they suggest to their clients each day. Market has identified the 5 stocks that cover experts are silently murmuring to their customers to acquire currently prior to the wider market catches on … as well as Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics presently has a “Buy” rating among experts, top-rated analysts believe these 5 stocks are much better purchases.

Leave a Reply

Your email address will not be published.